Pharmaceutical Technology

MAY 19, 2023

Multiple sclerosis (MS) is a primary autoimmune disease in which inflammation is a core contributor to the degeneration of the central nervous system (CNS), leading to neurological disability and affecting sensory, visual, motor, and autonomic systems. DMTs for MS have a high price tag, particularly in the US.

Prospecting 98

Prospecting Marketing Patients Leads 98

Pharmaceutical Technology

DECEMBER 5, 2022

Cannabinoid receptors are a popular therapeutic target for cannabinoid-based drugs in the treatment of pain, neurological disorders and inflammation, according to GlobalData’s Pharma Intelligence Centre Drugs database. This is closely followed by CB2 receptors in second place.

Medical 98

Medical Specialization Marketing Leads 98

Pharmaceutical Technology

FEBRUARY 10, 2023

This is not the first treatment to come with a high price tag. However, more highly innovative/high-cost treatments, within infectious disease and neurology space, are likely to enter the market for rare disorders, increasing the number of non-oncology RSAs.

Marketing 105

Marketing Medicine Leads Safety 105

Pharmaceutical Technology

MAY 2, 2023

While initially only approved for metastatic disease, ICIs have now moved into earlier disease settings, reducing the risk of disease progression and relapse. IO therapies come with a hefty price tag, with ICI therapies in the US typically exceeding $100,000, while cell therapies can exceed $400,000.

Physicians 52

Physicians Marketing Patients Manufacturing 52

PM360

SEPTEMBER 7, 2023

Mason learned that lesson while working with argenx to launch VYVGART (efgartigimod alfa-fcab), the first FDA-approved treatment of its kind for adults with anti-AChR antibody positive generalized myasthenia gravis (gMG), a rare autoimmune neuromuscular disease. We also put big pull tags on the little pouches that held the items.

Patients 105

Patients Pharma Education Doctors 105

European Pharmaceutical Review

MAY 11, 2023

Rare, genetic diseases like SMA are prime targets for gene therapy, but by their very nature, early signs can be difficult to recognise, delaying diagnosis and treatment. 1 This is assuming a $1M price tag for all gene therapies. In reality, this will vary by disease area and therapy. Available from: [link] [Internet] Cure SMA.

Food and Drug Administration 72

Food and Drug Administration Government Healthcare Healthcare 72

Pharmaceutical Technology

JANUARY 27, 2023

James George, a research professor at the University of Oklahoma Health Sciences Center, said Cablivi “adds a new aspect to treatment, the prompt recovery of platelets and prompt resolution of transient neurologic symptoms”. A refund up to 12 inpatient doses will also be offered for patients whose disease worsens while receiving treatment.

Patients 52

Patients Pharmaceutical Manufacturing Healthcare Provider 52